Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids
To evaluate and compare transforming growth factor β3 (TGF-β3) serum concentration in patients with uterine fibroids (UFs) without hormone treatment, treated with ulipristal acetate (UPA), and controls; to evaluate TGF-β3 concentrations in UF tissue in patients without hormone treatment and those treated with UPA; and to evaluate the correlations of age and body mass index (BMI) with TGF-β3 serum and UF tissue levels between the groups.
Source: fertstert.org
Ulipristal acetate decreases transforming growth factor β3 serum and tumor tissue concentrations in patients with uterine fibroids
Published in Embryology and Reproductive Medicine
More from Embryology and Reproductive MedicineMore posts in Embryology and Reproductive Medicine »
- Life after Stillbirth
- The possible impact of COVID 19 on fertility and ART
- Human embryonic stem cell–derived blastocyst-like spheroids resemble human trophectoderm during early implantation process
- What support is available for you in hospital if you lose your baby
- The role of total chromosomal disomy in human spermatozoa as a predictor of the outcome of pre-implantation genetic screening
Be First to Comment